![]() ![]() ![]() ![]() |
FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
![]() |
![]() |
![]() ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Product Name : Roche AmpliChip Cytochrome P450 Genotyping test and Affymetrix GeneChip Microarray Instrumentation System
Manufacturer: Roche Molecular Systems, Inc. and Affymetrix, Inc.
Address: 4300 Hacienda Dr. , Pleasanton , CA 94588 and 3380 Central Expy. , Santa Clara , CA 95051
Clearance Date: December 23, 2004
Clearance Letter: http://www.fda.gov/cdrh/pdf4/k042259.pdf
What is it? The Roche AmpliChip Cytochrome P450 Genotyping test for use on the Affymetrix GeneChip Microarray Instrumentation System is a new laboratory test system that will help doctors personalize treatment options for their patients. Doctors can use a patient’s genetic information to help them determine appropriate drugs and doses to prescribe. This will help minimize harmful drug reactions and prevent patients from being improperly treated with sub-optimal doses.
This system uses DNA extracted from a patient’s blood to detect certain common genetic mutations that alter the body’s ability to break down (metabolize) specific types of drugs. The enzyme produced from the gene that is tested, called cytochrome P4502D6 (CYP4502D6), is active in metabolizing many types of drugs including antidepressants, antipsychotics, beta-blockers, and some chemotherapy drugs. Variations in this gene can cause a patient to metabolize these drugs abnormally fast, abnormally slow, or not at all. For example, the same dose that is safe for a patient with one variation might be too high (and therefore toxic) to a patient with a different variation who cannot metabolize the drug.
With genetic information for this gene, many harmful reactions resulting from inappropriate dosing and treatment may be significantly reduced as clinicians can adjust the patient’s regimen accordingly.
How does it work? A doctor orders the genetic test in patients to gather information on the predicted metabolic activity of their enzyme encoded by CYP4502D6.
When is it used? The AmpliChip Cytochrome P450 Genotyping System is used to help a clinician determine if a patient has mutations in their CYP4502D6 gene that may affect their ability to metabolize certain drugs.
You should discuss these test results with your doctor because your body’s ability to metabolize a range of drug classes may be affected. This test is not a substitute for your doctor’s judgement and clinical experience. The test system is designed to aid the doctor in making individualized treatment decisions.
What will it accomplish? The AmpliChip Cytochrome P450 Genotyping System may help the doctor determine if a patient is at risk of adverse drug reactions or sub-optimal drug response.
When should it not be used? The AmpliChip Cytochrome P450 Genotyping System should not be used:
Additional information:
FDA Talk Paper: http://www.fda.gov/bbs/topics/news/2004/new01149.html
Information on CYP2D6 allele nomenclature : http://www.imm.ki.se/CYPalleles/cyp2d6.htm
Brief description of Cytochrome P4502D6: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=124030
Prescription Drug Information: http://www.fda.gov/cder/Offices/DDI/pathfinder.htm
Updated March 8, 2005
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH